MYRIAD GENETICS ($MYGN) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of -$0.03 per share, beating estimates of -$0.06 by $0.03. The company also reported revenue of $195,900,000, missing estimates of $204,575,535 by $-8,675,535.
You can see Quiver Quantitative's $MYGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MYRIAD GENETICS Hedge Fund Activity
We have seen 109 institutional investors add shares of MYRIAD GENETICS stock to their portfolio, and 135 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GLENVIEW CAPITAL MANAGEMENT, LLC added 2,895,794 shares (+229.5%) to their portfolio in Q4 2024, for an estimated $39,701,335
- LOOMIS SAYLES & CO L P removed 2,189,601 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $30,019,429
- CAMBER CAPITAL MANAGEMENT LP removed 850,000 shares (-21.5%) from their portfolio in Q4 2024, for an estimated $11,653,500
- MILLENNIUM MANAGEMENT LLC removed 831,315 shares (-16.1%) from their portfolio in Q4 2024, for an estimated $11,397,328
- STATE STREET CORP added 822,263 shares (+17.5%) to their portfolio in Q4 2024, for an estimated $11,273,225
- POINT72 ASSET MANAGEMENT, L.P. removed 715,107 shares (-67.2%) from their portfolio in Q4 2024, for an estimated $9,804,116
- WELLINGTON MANAGEMENT GROUP LLP removed 711,985 shares (-10.6%) from their portfolio in Q4 2024, for an estimated $9,761,314
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
MYRIAD GENETICS Government Contracts
We have seen $330,168 of award payments to $MYGN over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROLARIS TESTING: $239,904
- 24-GIMC LABORATORY SERVICES VENOR MYRIAD GENETICS LABORATORIES PERIOD OF PERFORMANCE 05 01 24-04 30 25: $60,344
- PROLARIS TESTING: $29,920
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
MYRIAD GENETICS Analyst Ratings
Wall Street analysts have issued reports on $MYGN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 03/12/2025
To track analyst ratings and price targets for MYRIAD GENETICS, check out Quiver Quantitative's $MYGN forecast page.
MYRIAD GENETICS Price Targets
Multiple analysts have issued price targets for $MYGN recently. We have seen 2 analysts offer price targets for $MYGN in the last 6 months, with a median target of $16.75.
Here are some recent targets:
- An analyst from Piper Sandler set a target price of $12.5 on 03/12/2025
- Puneet Souda from Leerink Partners set a target price of $21.0 on 12/09/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
